Heart Drug Trasylol May Boost Risk of Death
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on October 30, 2007
Foolowing the results of the a study on the efficacy and safety of Trasylol, a drug used to prevent excessive bleeding during heart bypass surgery, the FDA issued a warning that the drug also raises the risk of death in comparison to other drugs. Trasylol, also known as aprotinin, works by blocking enzymes that dissolve blood clots
Bayer said it believes Trasylol remains a safe and effective treatment option, but that the company would work with the FDA and regulators in other countries to re-evaluate the drug's risks and benefits and determine where any label changes are needed.
The FDA said such changes, as well as other, unspecified regulatory actions, may result.
Source: Fox News
Permalink: Heart Drug Trasylol May Boost Risk of Death
Tags: FDA heart+disease trasylol heart+surgery heart+bypass biotech risk+death drug+trasylol
Vote for Heart Drug Trasylol May Boost Risk of Death:
|
Rating: 9.00 out of 1 vote(s) cast.
|
Response from:
Tech|noob
These shirts are simply amazing. You see those hearts? They will glow, but only when one T-shirt is close
Response from:
Trusted.MD Network
Pioneering heart surgeon, Michael E. DeBakey died on Saturday (July 11) in Methodist Hospital Houston at the age of 99.
Who is Dr. Michael E. DeBakey?
father of modern cardiovascular surgery
invented scores of medical procedures and instruments
| RSS | |
|
| |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Follow us on Twitter! |
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
